GlobalData on MSN3d
Arbor to advance gene editing treatments with $73.9m fundingThe funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.
Medical Xpress on MSN9d
Breakthrough study led by CHLA neurologists links blood-brain barrier dysfunction and inflammation with Down syndrome regression disorderSantoro, MD, Director of the Neuroimmunology Program at Children’s Hospital Los Angeles, shows evidence of dysfunction of the ...
We asked an expert all about lorazepam, the addictive anti-anxiety medication that's been popping up on season 3 of 'The ...
"In contrast, very few neurons in the central nervous system itself expressed Cdkl ... Borja, Stephanie Bivona, Undiagnosed Diseases Network, Baylor College of Medicine Center for Precision ...
InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announced today that it has partnered with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback